4.8 Article

A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy

Journal

BIOMATERIALS
Volume 32, Issue 7, Pages 1986-1995

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2010.11.025

Keywords

Mesoporous silica nanospheres; beta-TCP scaffolds; Composite drug delivery system; Antitubercular drugs; Controlled release

Funding

  1. National Nature Science Foundation of China [20633090, 50823007]
  2. National 863 High-Tech Program [2007AA03Z317]
  3. CASKJCX Projects [KJCX2-YW-M02, KJCX2-YW-210]

Ask authors/readers for more resources

A composite scaffold drug delivery system (CS-DDS) for osteoarticular tuberculosis therapy has been prepared by loading bi-component drugs into a mesoporous silica nanoparticles (MSNs)-coated porous beta-TCP scaffold, which was followed by an additional bioactive glass coating. Such a CS-DDS showed high performances in the local and extremely sustained delivery of the bi-component antitubercular drugs and excellent biocompatibility. N-2 sorption isotherms indicated greatly increased surface area of the composites compared to pure beta-TCP scaffold, and the mesopores were around 2.6 nm which were large enough to encapsulate drugs such as isoniazide and rifampicin. The in vitro and in vivo release tests demonstrated extra sustained co-release profiles of rifampicin and isoniazide from such a CS-DDS, and both drug concentrations kept higher than their effective values to kill mycobacterium tuberculosis for as long as 42 days. The hepatic and renal function tests indicated that the CS-DDS had neglectable long-term lesions to liver and kidney. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available